Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway: a subgroup analysis of the Finesse Study
Background Monoclonal antibodies targeting the CGRP pathway are effective and safe for prophylactic treatment of episodic (EM) and chronic migraine (CM). In case of treatment failure of a CGRP pathway targeting mAb, physician has to decide whether using another anti-CGRP pathway mAb is useful. This...
Saved in:
| Published in | Journal of headache and pain Vol. 24; no. 1; pp. 59 - 11 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Milan
Springer Milan
23.05.2023
Springer Nature B.V BMC |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Background
Monoclonal antibodies targeting the CGRP pathway are effective and safe for prophylactic treatment of episodic (EM) and chronic migraine (CM). In case of treatment failure of a CGRP pathway targeting mAb, physician has to decide whether using another anti-CGRP pathway mAb is useful. This interim analysis of Finesse Study evaluates effectiveness of the anti-CGRP mAb fremanezumab in patients with a history of other prior anti-CGRP pathway mAb treatments (switch patients).
Methods
Finesse
, a non-interventional, prospective, multicentre, two-country (Germany-Austria) study observing migraine patients receiving fremanezumab in clinical routine. This subgroup analysis presents data on documented effectiveness over 3 months after the first dose of fremanezumab in switch patients. Effectiveness was evaluated based on reduction in average number of migraine days per month (MMDs), MIDAS and HIT-6 scores changes as well as in number of monthly days with acute migraine medication use.
Results
One hundred fifty-three out of 867 patients with a history of anti-CGRP pathway mAb treatment prior to initiation of fremanezumab were analysed. Switch to fremanezumab led to ≥ 50% MMD reduction in 42.8% of migraine patients, with higher response rate in EM (48.0%) than in CM patients (36.5%). A ≥ 30% MMD reduction was achieved by 58.7% in CM patients. After three months, monthly number of migraine days decreased by 6.4 ± 5.87 (baseline: 13.6 ± 6.5;
p
< 0.0001) in all patients, 5.2 ± 4.04 in EM and 7.7 ± 7.45 in CM patients. MIDAS scores decreased from 73.3 ± 56.8 (baseline) to 50.3 ± 52.9 (after 3 months;
p
= 0.0014), HIT-6 scores decreased from 65.9 ± 5.0 to 60.9 ± 7.2 (
p
< 0.0001). Concomitant use of acute migraine medication had decreased from 9.7 ± 4.98 (baseline) to 4.9 ± 3.66 (3 months) (
p
< 0.0001).
Conclusions
Our results show that about 42.8% of anti-CGRP pathway mAb-non-responder benefit from switching to fremanezumab. These results suggest that switching to fremanezumab may be a promising option for patients experiencing poor tolerability or inadequate efficacy with prior other anti-CGRP pathway mAb use.
Trial registration
Finesse
Study is registered on the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (EUPAS44606).
Graphical Abstract |
|---|---|
| AbstractList | BackgroundMonoclonal antibodies targeting the CGRP pathway are effective and safe for prophylactic treatment of episodic (EM) and chronic migraine (CM). In case of treatment failure of a CGRP pathway targeting mAb, physician has to decide whether using another anti-CGRP pathway mAb is useful. This interim analysis of Finesse Study evaluates effectiveness of the anti-CGRP mAb fremanezumab in patients with a history of other prior anti-CGRP pathway mAb treatments (switch patients).MethodsFinesse, a non-interventional, prospective, multicentre, two-country (Germany-Austria) study observing migraine patients receiving fremanezumab in clinical routine. This subgroup analysis presents data on documented effectiveness over 3 months after the first dose of fremanezumab in switch patients. Effectiveness was evaluated based on reduction in average number of migraine days per month (MMDs), MIDAS and HIT-6 scores changes as well as in number of monthly days with acute migraine medication use.ResultsOne hundred fifty-three out of 867 patients with a history of anti-CGRP pathway mAb treatment prior to initiation of fremanezumab were analysed. Switch to fremanezumab led to ≥ 50% MMD reduction in 42.8% of migraine patients, with higher response rate in EM (48.0%) than in CM patients (36.5%). A ≥ 30% MMD reduction was achieved by 58.7% in CM patients. After three months, monthly number of migraine days decreased by 6.4 ± 5.87 (baseline: 13.6 ± 6.5; p < 0.0001) in all patients, 5.2 ± 4.04 in EM and 7.7 ± 7.45 in CM patients. MIDAS scores decreased from 73.3 ± 56.8 (baseline) to 50.3 ± 52.9 (after 3 months; p = 0.0014), HIT-6 scores decreased from 65.9 ± 5.0 to 60.9 ± 7.2 (p < 0.0001). Concomitant use of acute migraine medication had decreased from 9.7 ± 4.98 (baseline) to 4.9 ± 3.66 (3 months) (p < 0.0001).ConclusionsOur results show that about 42.8% of anti-CGRP pathway mAb-non-responder benefit from switching to fremanezumab. These results suggest that switching to fremanezumab may be a promising option for patients experiencing poor tolerability or inadequate efficacy with prior other anti-CGRP pathway mAb use.Trial registrationFinesse Study is registered on the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (EUPAS44606). Monoclonal antibodies targeting the CGRP pathway are effective and safe for prophylactic treatment of episodic (EM) and chronic migraine (CM). In case of treatment failure of a CGRP pathway targeting mAb, physician has to decide whether using another anti-CGRP pathway mAb is useful. This interim analysis of Finesse Study evaluates effectiveness of the anti-CGRP mAb fremanezumab in patients with a history of other prior anti-CGRP pathway mAb treatments (switch patients).BACKGROUNDMonoclonal antibodies targeting the CGRP pathway are effective and safe for prophylactic treatment of episodic (EM) and chronic migraine (CM). In case of treatment failure of a CGRP pathway targeting mAb, physician has to decide whether using another anti-CGRP pathway mAb is useful. This interim analysis of Finesse Study evaluates effectiveness of the anti-CGRP mAb fremanezumab in patients with a history of other prior anti-CGRP pathway mAb treatments (switch patients).FINESSE, a non-interventional, prospective, multicentre, two-country (Germany-Austria) study observing migraine patients receiving fremanezumab in clinical routine. This subgroup analysis presents data on documented effectiveness over 3 months after the first dose of fremanezumab in switch patients. Effectiveness was evaluated based on reduction in average number of migraine days per month (MMDs), MIDAS and HIT-6 scores changes as well as in number of monthly days with acute migraine medication use.METHODSFINESSE, a non-interventional, prospective, multicentre, two-country (Germany-Austria) study observing migraine patients receiving fremanezumab in clinical routine. This subgroup analysis presents data on documented effectiveness over 3 months after the first dose of fremanezumab in switch patients. Effectiveness was evaluated based on reduction in average number of migraine days per month (MMDs), MIDAS and HIT-6 scores changes as well as in number of monthly days with acute migraine medication use.One hundred fifty-three out of 867 patients with a history of anti-CGRP pathway mAb treatment prior to initiation of fremanezumab were analysed. Switch to fremanezumab led to ≥ 50% MMD reduction in 42.8% of migraine patients, with higher response rate in EM (48.0%) than in CM patients (36.5%). A ≥ 30% MMD reduction was achieved by 58.7% in CM patients. After three months, monthly number of migraine days decreased by 6.4 ± 5.87 (baseline: 13.6 ± 6.5; p < 0.0001) in all patients, 5.2 ± 4.04 in EM and 7.7 ± 7.45 in CM patients. MIDAS scores decreased from 73.3 ± 56.8 (baseline) to 50.3 ± 52.9 (after 3 months; p = 0.0014), HIT-6 scores decreased from 65.9 ± 5.0 to 60.9 ± 7.2 (p < 0.0001). Concomitant use of acute migraine medication had decreased from 9.7 ± 4.98 (baseline) to 4.9 ± 3.66 (3 months) (p < 0.0001).RESULTSOne hundred fifty-three out of 867 patients with a history of anti-CGRP pathway mAb treatment prior to initiation of fremanezumab were analysed. Switch to fremanezumab led to ≥ 50% MMD reduction in 42.8% of migraine patients, with higher response rate in EM (48.0%) than in CM patients (36.5%). A ≥ 30% MMD reduction was achieved by 58.7% in CM patients. After three months, monthly number of migraine days decreased by 6.4 ± 5.87 (baseline: 13.6 ± 6.5; p < 0.0001) in all patients, 5.2 ± 4.04 in EM and 7.7 ± 7.45 in CM patients. MIDAS scores decreased from 73.3 ± 56.8 (baseline) to 50.3 ± 52.9 (after 3 months; p = 0.0014), HIT-6 scores decreased from 65.9 ± 5.0 to 60.9 ± 7.2 (p < 0.0001). Concomitant use of acute migraine medication had decreased from 9.7 ± 4.98 (baseline) to 4.9 ± 3.66 (3 months) (p < 0.0001).Our results show that about 42.8% of anti-CGRP pathway mAb-non-responder benefit from switching to fremanezumab. These results suggest that switching to fremanezumab may be a promising option for patients experiencing poor tolerability or inadequate efficacy with prior other anti-CGRP pathway mAb use.CONCLUSIONSOur results show that about 42.8% of anti-CGRP pathway mAb-non-responder benefit from switching to fremanezumab. These results suggest that switching to fremanezumab may be a promising option for patients experiencing poor tolerability or inadequate efficacy with prior other anti-CGRP pathway mAb use.FINESSE Study is registered on the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (EUPAS44606).TRIAL REGISTRATIONFINESSE Study is registered on the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (EUPAS44606). Abstract Background Monoclonal antibodies targeting the CGRP pathway are effective and safe for prophylactic treatment of episodic (EM) and chronic migraine (CM). In case of treatment failure of a CGRP pathway targeting mAb, physician has to decide whether using another anti-CGRP pathway mAb is useful. This interim analysis of Finesse Study evaluates effectiveness of the anti-CGRP mAb fremanezumab in patients with a history of other prior anti-CGRP pathway mAb treatments (switch patients). Methods Finesse, a non-interventional, prospective, multicentre, two-country (Germany-Austria) study observing migraine patients receiving fremanezumab in clinical routine. This subgroup analysis presents data on documented effectiveness over 3 months after the first dose of fremanezumab in switch patients. Effectiveness was evaluated based on reduction in average number of migraine days per month (MMDs), MIDAS and HIT-6 scores changes as well as in number of monthly days with acute migraine medication use. Results One hundred fifty-three out of 867 patients with a history of anti-CGRP pathway mAb treatment prior to initiation of fremanezumab were analysed. Switch to fremanezumab led to ≥ 50% MMD reduction in 42.8% of migraine patients, with higher response rate in EM (48.0%) than in CM patients (36.5%). A ≥ 30% MMD reduction was achieved by 58.7% in CM patients. After three months, monthly number of migraine days decreased by 6.4 ± 5.87 (baseline: 13.6 ± 6.5; p < 0.0001) in all patients, 5.2 ± 4.04 in EM and 7.7 ± 7.45 in CM patients. MIDAS scores decreased from 73.3 ± 56.8 (baseline) to 50.3 ± 52.9 (after 3 months; p = 0.0014), HIT-6 scores decreased from 65.9 ± 5.0 to 60.9 ± 7.2 (p < 0.0001). Concomitant use of acute migraine medication had decreased from 9.7 ± 4.98 (baseline) to 4.9 ± 3.66 (3 months) (p < 0.0001). Conclusions Our results show that about 42.8% of anti-CGRP pathway mAb-non-responder benefit from switching to fremanezumab. These results suggest that switching to fremanezumab may be a promising option for patients experiencing poor tolerability or inadequate efficacy with prior other anti-CGRP pathway mAb use. Trial registration Finesse Study is registered on the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (EUPAS44606). Graphical Abstract Monoclonal antibodies targeting the CGRP pathway are effective and safe for prophylactic treatment of episodic (EM) and chronic migraine (CM). In case of treatment failure of a CGRP pathway targeting mAb, physician has to decide whether using another anti-CGRP pathway mAb is useful. This interim analysis of Finesse Study evaluates effectiveness of the anti-CGRP mAb fremanezumab in patients with a history of other prior anti-CGRP pathway mAb treatments (switch patients). FINESSE, a non-interventional, prospective, multicentre, two-country (Germany-Austria) study observing migraine patients receiving fremanezumab in clinical routine. This subgroup analysis presents data on documented effectiveness over 3 months after the first dose of fremanezumab in switch patients. Effectiveness was evaluated based on reduction in average number of migraine days per month (MMDs), MIDAS and HIT-6 scores changes as well as in number of monthly days with acute migraine medication use. One hundred fifty-three out of 867 patients with a history of anti-CGRP pathway mAb treatment prior to initiation of fremanezumab were analysed. Switch to fremanezumab led to ≥ 50% MMD reduction in 42.8% of migraine patients, with higher response rate in EM (48.0%) than in CM patients (36.5%). A ≥ 30% MMD reduction was achieved by 58.7% in CM patients. After three months, monthly number of migraine days decreased by 6.4 ± 5.87 (baseline: 13.6 ± 6.5; p < 0.0001) in all patients, 5.2 ± 4.04 in EM and 7.7 ± 7.45 in CM patients. MIDAS scores decreased from 73.3 ± 56.8 (baseline) to 50.3 ± 52.9 (after 3 months; p = 0.0014), HIT-6 scores decreased from 65.9 ± 5.0 to 60.9 ± 7.2 (p < 0.0001). Concomitant use of acute migraine medication had decreased from 9.7 ± 4.98 (baseline) to 4.9 ± 3.66 (3 months) (p < 0.0001). Our results show that about 42.8% of anti-CGRP pathway mAb-non-responder benefit from switching to fremanezumab. These results suggest that switching to fremanezumab may be a promising option for patients experiencing poor tolerability or inadequate efficacy with prior other anti-CGRP pathway mAb use. FINESSE Study is registered on the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (EUPAS44606). Background Monoclonal antibodies targeting the CGRP pathway are effective and safe for prophylactic treatment of episodic (EM) and chronic migraine (CM). In case of treatment failure of a CGRP pathway targeting mAb, physician has to decide whether using another anti-CGRP pathway mAb is useful. This interim analysis of Finesse Study evaluates effectiveness of the anti-CGRP mAb fremanezumab in patients with a history of other prior anti-CGRP pathway mAb treatments (switch patients). Methods Finesse , a non-interventional, prospective, multicentre, two-country (Germany-Austria) study observing migraine patients receiving fremanezumab in clinical routine. This subgroup analysis presents data on documented effectiveness over 3 months after the first dose of fremanezumab in switch patients. Effectiveness was evaluated based on reduction in average number of migraine days per month (MMDs), MIDAS and HIT-6 scores changes as well as in number of monthly days with acute migraine medication use. Results One hundred fifty-three out of 867 patients with a history of anti-CGRP pathway mAb treatment prior to initiation of fremanezumab were analysed. Switch to fremanezumab led to ≥ 50% MMD reduction in 42.8% of migraine patients, with higher response rate in EM (48.0%) than in CM patients (36.5%). A ≥ 30% MMD reduction was achieved by 58.7% in CM patients. After three months, monthly number of migraine days decreased by 6.4 ± 5.87 (baseline: 13.6 ± 6.5; p < 0.0001) in all patients, 5.2 ± 4.04 in EM and 7.7 ± 7.45 in CM patients. MIDAS scores decreased from 73.3 ± 56.8 (baseline) to 50.3 ± 52.9 (after 3 months; p = 0.0014), HIT-6 scores decreased from 65.9 ± 5.0 to 60.9 ± 7.2 ( p < 0.0001). Concomitant use of acute migraine medication had decreased from 9.7 ± 4.98 (baseline) to 4.9 ± 3.66 (3 months) ( p < 0.0001). Conclusions Our results show that about 42.8% of anti-CGRP pathway mAb-non-responder benefit from switching to fremanezumab. These results suggest that switching to fremanezumab may be a promising option for patients experiencing poor tolerability or inadequate efficacy with prior other anti-CGRP pathway mAb use. Trial registration Finesse Study is registered on the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (EUPAS44606). Graphical Abstract |
| ArticleNumber | 59 |
| Author | Straube, Andreas Kraya, Torsten Hamann, Xenia Broessner, Gregor Gaul, Charly Hipp, Joachim Neeb, Lars |
| Author_xml | – sequence: 1 givenname: Andreas surname: Straube fullname: Straube, Andreas email: Andreas.Straube@med.uni-muenchen.de organization: Department of Neurology, University Hospital, LMU Munich – sequence: 2 givenname: Gregor surname: Broessner fullname: Broessner, Gregor organization: Department of Neurology, Innsbruck Medical University – sequence: 3 givenname: Charly surname: Gaul fullname: Gaul, Charly organization: Headache Center Frankfurt – sequence: 4 givenname: Xenia surname: Hamann fullname: Hamann, Xenia organization: Teva GmbH – sequence: 5 givenname: Joachim surname: Hipp fullname: Hipp, Joachim organization: Teva GmbH – sequence: 6 givenname: Torsten surname: Kraya fullname: Kraya, Torsten organization: Department of Neurology, Hospital Sankt Georg Leipzig gGmbH, Department of Neurology, Headache Center Halle, University Hospital Halle – sequence: 7 givenname: Lars surname: Neeb fullname: Neeb, Lars organization: Helios Global Health, Department of Neurology, Charité-Universitätsmedizin Berlin |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37221478$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9Uk1v1DAQjVAR_YA_wAFZ4sIlYDtx7HBB1YqWSpVABc7WxHGyXiX2YjtdLb8GiX_CL8PZLaXtoSfbM--9Gc-84-zAOquz7CXBbwkR1btAMKnLHNMix4TVRU6fZEeE0DqnBecHd-6H2XEIK4wpLgR7lh0WnFJScnGU_b7SMOQb54cW6a7TKpprbXUIyHWo83oEq39OIzTIWLSGaLSNAW1MXKLR9B6M1Sikp1oa2yeCG__8AuviUns0njYogu91nHMphBbnV19mleUGtu8RoDA1vXfTGoGFYRvMruoMPDNzDxp9jVO7fZ497WAI-sXNeZJ9P_v4bfEpv_x8frE4vcwVK0nMGW470VSKVm2nWQW40rwihPBGV5oxrkrCmqrFBTAgUGAQbdkWVSEwVYTXZXGSXex1WwcrufZmBL-VDozcBZzvJfho1KCl6pgAKBVLdcqmAICG87IVRLAaq7pNWh_2WuupGXWr0tg8DPdE72esWcreXUuSlsQ5E0nhzY2Cdz8mHaIcTVB6GNJG3BQkTcV4WWNGEvT1A-jKTT6NdIfiQnDGaEK9utvSbS__zJAAdA9Q3oXgdXcLIVjOjpN7x8nkOLlznJxVxQOSMjH5xM3fMsPj1GJPDamO7bX_3_YjrL-ZxO36 |
| CitedBy_id | crossref_primary_10_1080_14712598_2024_2354386 crossref_primary_10_1016_j_neurop_2024_100168 crossref_primary_10_1017_cjn_2024_285 crossref_primary_10_1186_s10194_024_01788_1 crossref_primary_10_1016_j_neurol_2024_09_008 crossref_primary_10_3389_fneur_2023_1226591 crossref_primary_10_3988_jcn_2023_0311 crossref_primary_10_1111_head_14903 crossref_primary_10_1038_s41598_024_72282_6 crossref_primary_10_1111_head_14827 crossref_primary_10_1177_03331024241288875 crossref_primary_10_1111_ene_16542 crossref_primary_10_1007_s15005_024_4139_9 crossref_primary_10_1111_head_14865 crossref_primary_10_14412_2074_2711_2024_3_72_78 crossref_primary_10_1007_s00940_024_4710_y crossref_primary_10_1080_14737175_2025_2461766 crossref_primary_10_1186_s10194_023_01698_8 crossref_primary_10_1177_25158163241292307 crossref_primary_10_1186_s10194_024_01790_7 crossref_primary_10_1002_rpm_20240006 crossref_primary_10_1080_17512433_2024_2417655 crossref_primary_10_2169_internalmedicine_4360_24 crossref_primary_10_1177_03331024241291574 |
| Cites_doi | 10.1056/NEJMoa1709038 10.1212/WNL.0000000000010740 10.1097/MD.0000000000018483 10.1097/WCO.0000000000000438 10.1111/1440-1681.13700 10.1007/s00115-022-01403-1 10.1016/S0304-3959(00)00305-5 10.1136/ejhpharm-2021-002946 10.1002/ana.410330109 10.2217/pmt-2020-0030 10.1186/s10194-022-01498-6 10.1007/s42451-023-00550-2 10.1038/304129a0 10.1111/head.13729 10.1159/000518899 10.1111/head.13081 10.1177/03331024211048765 10.7554/eLife.77146 10.1186/s10194-022-01431-x 10.1177/0333102417738202 10.1007/s40263-021-00834-9 10.1177/0333102420983282 10.1186/s10194-021-01323-6 10.1016/S0140-6736(04)15440-8 10.1177/03331024211018137 10.1177/0333102410379890 10.1186/s10194-022-01415-x |
| ContentType | Journal Article |
| Copyright | The Author(s) 2023 2023. The Author(s). The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2023 – notice: 2023. The Author(s). – notice: The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7RV 7TK 7X7 7XB 88E 88G 8AO 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH GNUQQ K9. M0S M1P M2M NAPCQ PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS PSYQQ Q9U 7X8 5PM DOA |
| DOI | 10.1186/s10194-023-01593-2 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Neurosciences Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Psychology Database (Alumni) ProQuest Pharma Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni) PML(ProQuest Medical Library) Psychology Database (Proquest) ProQuest Nursing and Allied Health Premium ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Psychology ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Psychology Journals (Alumni) Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest Psychology Journals ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: Directory of Open Access Journals (DOAJ) url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1129-2377 |
| EndPage | 11 |
| ExternalDocumentID | oai_doaj_org_article_cf58aa4c556a4b3aaab774d818590c9d PMC10207758 37221478 10_1186_s10194_023_01593_2 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: Universitätsklinik München (6933) – fundername: ; |
| GroupedDBID | --- -5E -5G -A0 -BR .86 0R~ 123 29K 36B 3V. 4.4 40G 53G 5VS 67Z 6NX 7RV 7X7 88E 8AO 8FI 8FJ 8TC 8UJ AAFWJ AAJSJ AAKDD AAKKN AAWTL ABEEZ ABIVO ABMNI ABUWG ACACY ACGFS ACPRK ACULB ADBBV ADINQ AENEX AFBBN AFGXO AFKRA AFPKN AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AOIJS AZQEC BA0 BAPOH BAWUL BCNDV BENPR BFQNJ BGNMA BKEYQ BMC BPHCQ BVXVI C24 C6C CAG CCPQU CS3 CSCUP D-I DIK DL5 DU5 DWQXO EBLON EBS EMB EMOBN EX3 F5P FYUFA GNUQQ GROUPED_DOAJ GXS HG6 HMCUK HYE HZ~ I09 IXC IXE IZQ I~X KDC KPH KQ8 LAS M1P M2M M48 M4Y M~E NAPCQ NB0 NU0 OAM OK1 PGMZT PIMPY PQQKQ PROAC PSQYO PSYQQ PZZ Q2X RNS RPM RPX RRX RSV S27 SDH SMD SOJ SV3 T13 TSK U2A UKHRP VC2 WJK WOW Z7U Z82 Z87 ~KM AASML AAYXX CITATION PHGZM PHGZT CGR CUY CVF ECM EIF NPM 7TK 7XB 8FK K9. PJZUB PKEHL PPXIY PQEST PQUKI PRINS Q9U 7X8 5PM ADUKV PUEGO |
| ID | FETCH-LOGICAL-c541t-50df8b6c26dfe56a06e761117be6e557c415b6d03a5a1a30a8d4d363802c17943 |
| IEDL.DBID | M48 |
| ISSN | 1129-2377 1129-2369 |
| IngestDate | Wed Aug 27 01:21:55 EDT 2025 Thu Aug 21 18:37:49 EDT 2025 Fri Jul 11 02:16:17 EDT 2025 Fri Jul 25 04:12:25 EDT 2025 Wed Feb 19 02:23:56 EST 2025 Tue Jul 01 02:56:54 EDT 2025 Thu Apr 24 22:58:33 EDT 2025 Fri Feb 21 02:43:38 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Calcitonin gene-related peptide Fremanezumab Non-responder Migraine |
| Language | English |
| License | 2023. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c541t-50df8b6c26dfe56a06e761117be6e557c415b6d03a5a1a30a8d4d363802c17943 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://www.proquest.com/docview/2817887552?pq-origsite=%requestingapplication% |
| PMID | 37221478 |
| PQID | 2817887552 |
| PQPubID | 43392 |
| PageCount | 11 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_cf58aa4c556a4b3aaab774d818590c9d pubmedcentral_primary_oai_pubmedcentral_nih_gov_10207758 proquest_miscellaneous_2818749051 proquest_journals_2817887552 pubmed_primary_37221478 crossref_primary_10_1186_s10194_023_01593_2 crossref_citationtrail_10_1186_s10194_023_01593_2 springer_journals_10_1186_s10194_023_01593_2 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2023-05-23 |
| PublicationDateYYYYMMDD | 2023-05-23 |
| PublicationDate_xml | – month: 05 year: 2023 text: 2023-05-23 day: 23 |
| PublicationDecade | 2020 |
| PublicationPlace | Milan |
| PublicationPlace_xml | – name: Milan – name: England – name: Milano |
| PublicationSubtitle | Official Journal of the "European Headache Federation" and of "Lifting The Burden - The Global Campaign against Headache" |
| PublicationTitle | Journal of headache and pain |
| PublicationTitleAbbrev | J Headache Pain |
| PublicationTitleAlternate | J Headache Pain |
| PublicationYear | 2023 |
| Publisher | Springer Milan Springer Nature B.V BMC |
| Publisher_xml | – name: Springer Milan – name: Springer Nature B.V – name: BMC |
| References | EdvinssonLThe trigeminovascular pathway: role of CGRP and CGRP receptors in migraineHeadache201757Suppl 2475510.1111/head.1308128485848 FrankFUlmerHSidoroffVBroessnerGCGRP-antibodies, topiramate and botulinum toxin type A in episodic and chronic migraine: a systematic review and meta-analysisCephalalgia20214112223910.1177/03331024211018137341305258506070 BhaktaMVuongTMigraine therapeutics differentially modulate the CGRP pathwayCephalalgia20214149951410.1177/0333102420983282336269228054164 BarbantiPEgeoGAurilliaCPredictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patientsJ Headache Pain2022231381:CAS:528:DC%2BB38XivVWisb7L10.1186/s10194-022-01498-6363166489623966 DriessenMTCohenJMThompsonSFReal-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraineJ Headache Pain202223561:CAS:528:DC%2BB38XhtlSms7zE10.1186/s10194-022-01415-x355781829109352 ZiegelerCMayANon-responders to treatment with antibodies to the CGRP-receptor may profit from a switch of antibody classHeadache20206046947010.1111/head.1372931872439 SilbersteinSDDodickDWBigalMEFremanezumab for the preventive treatment of chronic migraineN Engl J Med2017377211321221:CAS:528:DC%2BC1cXms1Or10.1056/NEJMoa170903829171818 MitsikostasDDReuterUCalcitonin gene-related peptide monoclonal antibodies for migraine prevention: comparisons across randomized controlled studiesCurr Opin Neurol2017302722801:CAS:528:DC%2BC2sXmsFaiur4%3D10.1097/WCO.000000000000043828240610 RosenfeldMGMermodJJAmaraSGSwansonLWSawchenkoPERivierJValeWWEvansRMProduction of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processingNature19833041291351:CAS:528:DyaL3sXlslSmtrs%3D10.1038/304129a06346105 BasedauHSturmLMMigraine monoclonal antibodies against CGRP change brain activity depending on ligand or receptor target - an fMRI studyElife202211e771461:CAS:528:DC%2BB38XitlCmsLfE10.7554/eLife.77146356047559126581 Zhu C, Guan J et al. (2019) Erenumab safety and efficacy in migraine: A systematic review and meta-analysis of randomized clinical trials. Medicine 98:e184883 ZiegelerCMehnertJCentral effects of erenumab in migraine patients: an event-related functional imaging studyNeurology202095e2794e28021:CAS:528:DC%2BB3cXitlCjtLzF10.1212/WNL.000000000001074032917805 YMT, Hartoyo V, Hariyanto, Efficacy and safety of eptinezumab as preventive treatment for episodic/chronic migraine: a systematic review and meta-analysisClin Exp Pharmacol Physiol202249115611681:CAS:528:DC%2BB38XhvFWns7nO10.1111/1440-1681.13700 World Health Organization (2012) Headache disorders Fact Sheet N°277, Geneva; https://www.who.int/news-room/fact-sheets/detail/headache-disorders. (retrieved 01.25.2023) Briceño-Casado MdP (2021) Gil-Sierra MD, De-la-Calle_Riaguas B (2021) Switching of monoclonal antibodies against calcitonin gene-related peptide in chronic migraine in clinical practice: a case series. Eur J Hosp Pharm. 14:ejhpharm-2021-002946. https://doi.org/10.1136/ejhpharm-2021-002946 OlesenJHeadache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd editionCephalalgia201838121110.1177/0333102417738202 Robbins L et al. (2019) Pract Pain Manag. CGRP Monoclonal Antibodies for Chronic Migraine: Year 1 of Clinical Use. https://www.practicalpainmangement.com/pain/headache/cgrp-monoclonal-antibodies-chronic-migraine-year-1-clinical-use OvereemLHPeikertAHofackerMDEffect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: a multi-center retrospective cohort studyCephalalgia20214229130110.1177/03331024211048765346442038988456 Diener H.-C., Förderreuther S, Kropp P. et al. (2022) Therapie der Migräneattacke und Prophylaxe der Migräne, S1-Leitlinie, 2022, DGN und DMKG, in: Deutsche Gesellschaft für Neurologie (Hrsg.), Leitlinien für Diagnostik und Therapie in der Neurologie. https://doi.org/leitlinie/therapie-der-migraneattacke-und-prophylaxeder-migrane-2022 SchefflerASchenkHWurthmannSCGRP antibody therapy in patients with drug resistant migraine and chronic daily headache: a real-world experienceJ Headache Pain2021221111:CAS:528:DC%2BB38XjtVyksrY%3D10.1186/s10194-021-01323-6345443598454157 StewartWFLiptonRBKolodnerKBValidity of the Migraine Disability Assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferersPain200088415210.1016/S0304-3959(00)00305-511098098 SimonRPAminoffMJGreenbergDAClinical Neurology20097A Lange medical bookMcGraw-Hill Professional Publishing, New York, USA SaccoSAminFAshinaMEuropean Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 updateJ Headache Pain2022236710.1186/s10194-022-01431-x356907239188162 FrerichsLMFriedmanDIGalcanezumab for the prevention of migrainePain Manag20211110111210.2217/pmt-2020-003033291980 SilbersteinSDMigraineThe Lancet20043633813911:CAS:528:DC%2BD2cXptVehsw%3D%3D10.1016/S0140-6736(04)15440-8 GoadsbyPJEdvinssonLThe trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and catsAnn Neurol19933348561:STN:280:DyaK3s3mtlGqsw%3D%3D10.1002/ana.4103301098388188 Goßrau G, Förderreuther S, Ruscheweyh R, Ruschil V, Sprenger T, Lewis D, et al. (2023) Konsensusstatement der Migräne- und Kopfschmerzgesellschaften (DMKG, ÖKSG & SKG) zur Therapiedauer der medikamentösen Migräneprophylaxe [Consensus statement of the migraine and headache societies (DMKG, ÖKSG, and SKG) on the duration of pharmacological migraine prophylaxis]. Nervenarzt. 94(4):306-317. German. https://doi.org/10.1007/s00115-022-01403-1. Epub 2022 Oct 26. Erratum in: Nervenarzt. 2023 Jan 16;: PMID: 36287216; PMCID: PMC9607745 OvereemLHRaffaelliBMecklenburgJKeldermanTNeebLReuterUIndirect comparison of topiramate and monoclonal antibodies against CGRP or its receptor for the prophylaxis of episodic migraine: a systematic review with meta-analysisCNS Drugs2021358058201:CAS:528:DC%2BB3MXitVWqurnI10.1007/s40263-021-00834-9342726888354912 YangMRendas-BaumRVaronSFValidation of the Headache Impact Test (HIT-6™) across episodic and chronic migraineCephalalgia2011313576710.1177/0333102410379890208198423057423 RuizIPFerrándezJS-RFonfríaACEarly experiences in switching between monoclonal antibodies in patients with nonresponsive migraine in Spain: a case seriesEur Neurol202110.1159/000518899 SD Silberstein (1593_CR8) 2017; 377 C Ziegeler (1593_CR20) 2020; 95 M Yang (1593_CR16) 2011; 31 YMT, Hartoyo V, Hariyanto (1593_CR9) 2022; 49 LH Overeem (1593_CR13) 2021; 35 1593_CR28 MT Driessen (1593_CR27) 2022; 23 1593_CR29 J Olesen (1593_CR17) 2018; 38 1593_CR24 1593_CR25 S Sacco (1593_CR18) 2022; 23 A Scheffler (1593_CR30) 2021; 22 LM Frerichs (1593_CR7) 2021; 11 C Ziegeler (1593_CR22) 2020; 60 L Edvinsson (1593_CR6) 2017; 57 1593_CR2 IP Ruiz (1593_CR23) 2021 MG Rosenfeld (1593_CR4) 1983; 304 SD Silberstein (1593_CR3) 2004; 363 RP Simon (1593_CR1) 2009 M Bhakta (1593_CR19) 2021; 41 WF Stewart (1593_CR15) 2000; 88 PJ Goadsby (1593_CR5) 1993; 33 1593_CR10 F Frank (1593_CR12) 2021; 41 H Basedau (1593_CR21) 2022; 11 LH Overeem (1593_CR26) 2021; 42 P Barbanti (1593_CR14) 2022; 23 DD Mitsikostas (1593_CR11) 2017; 30 |
| References_xml | – reference: SimonRPAminoffMJGreenbergDAClinical Neurology20097A Lange medical bookMcGraw-Hill Professional Publishing, New York, USA – reference: GoadsbyPJEdvinssonLThe trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and catsAnn Neurol19933348561:STN:280:DyaK3s3mtlGqsw%3D%3D10.1002/ana.4103301098388188 – reference: BarbantiPEgeoGAurilliaCPredictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patientsJ Headache Pain2022231381:CAS:528:DC%2BB38XivVWisb7L10.1186/s10194-022-01498-6363166489623966 – reference: SchefflerASchenkHWurthmannSCGRP antibody therapy in patients with drug resistant migraine and chronic daily headache: a real-world experienceJ Headache Pain2021221111:CAS:528:DC%2BB38XjtVyksrY%3D10.1186/s10194-021-01323-6345443598454157 – reference: SilbersteinSDMigraineThe Lancet20043633813911:CAS:528:DC%2BD2cXptVehsw%3D%3D10.1016/S0140-6736(04)15440-8 – reference: YMT, Hartoyo V, Hariyanto, Efficacy and safety of eptinezumab as preventive treatment for episodic/chronic migraine: a systematic review and meta-analysisClin Exp Pharmacol Physiol202249115611681:CAS:528:DC%2BB38XhvFWns7nO10.1111/1440-1681.13700 – reference: OlesenJHeadache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd editionCephalalgia201838121110.1177/0333102417738202 – reference: OvereemLHRaffaelliBMecklenburgJKeldermanTNeebLReuterUIndirect comparison of topiramate and monoclonal antibodies against CGRP or its receptor for the prophylaxis of episodic migraine: a systematic review with meta-analysisCNS Drugs2021358058201:CAS:528:DC%2BB3MXitVWqurnI10.1007/s40263-021-00834-9342726888354912 – reference: World Health Organization (2012) Headache disorders Fact Sheet N°277, Geneva; https://www.who.int/news-room/fact-sheets/detail/headache-disorders. (retrieved 01.25.2023) – reference: Briceño-Casado MdP (2021) Gil-Sierra MD, De-la-Calle_Riaguas B (2021) Switching of monoclonal antibodies against calcitonin gene-related peptide in chronic migraine in clinical practice: a case series. Eur J Hosp Pharm. 14:ejhpharm-2021-002946. https://doi.org/10.1136/ejhpharm-2021-002946 – reference: Robbins L et al. (2019) Pract Pain Manag. CGRP Monoclonal Antibodies for Chronic Migraine: Year 1 of Clinical Use. https://www.practicalpainmangement.com/pain/headache/cgrp-monoclonal-antibodies-chronic-migraine-year-1-clinical-use – reference: MitsikostasDDReuterUCalcitonin gene-related peptide monoclonal antibodies for migraine prevention: comparisons across randomized controlled studiesCurr Opin Neurol2017302722801:CAS:528:DC%2BC2sXmsFaiur4%3D10.1097/WCO.000000000000043828240610 – reference: YangMRendas-BaumRVaronSFValidation of the Headache Impact Test (HIT-6™) across episodic and chronic migraineCephalalgia2011313576710.1177/0333102410379890208198423057423 – reference: ZiegelerCMehnertJCentral effects of erenumab in migraine patients: an event-related functional imaging studyNeurology202095e2794e28021:CAS:528:DC%2BB3cXitlCjtLzF10.1212/WNL.000000000001074032917805 – reference: SilbersteinSDDodickDWBigalMEFremanezumab for the preventive treatment of chronic migraineN Engl J Med2017377211321221:CAS:528:DC%2BC1cXms1Or10.1056/NEJMoa170903829171818 – reference: FrankFUlmerHSidoroffVBroessnerGCGRP-antibodies, topiramate and botulinum toxin type A in episodic and chronic migraine: a systematic review and meta-analysisCephalalgia20214112223910.1177/03331024211018137341305258506070 – reference: BhaktaMVuongTMigraine therapeutics differentially modulate the CGRP pathwayCephalalgia20214149951410.1177/0333102420983282336269228054164 – reference: Goßrau G, Förderreuther S, Ruscheweyh R, Ruschil V, Sprenger T, Lewis D, et al. (2023) Konsensusstatement der Migräne- und Kopfschmerzgesellschaften (DMKG, ÖKSG & SKG) zur Therapiedauer der medikamentösen Migräneprophylaxe [Consensus statement of the migraine and headache societies (DMKG, ÖKSG, and SKG) on the duration of pharmacological migraine prophylaxis]. Nervenarzt. 94(4):306-317. German. https://doi.org/10.1007/s00115-022-01403-1. Epub 2022 Oct 26. Erratum in: Nervenarzt. 2023 Jan 16;: PMID: 36287216; PMCID: PMC9607745 – reference: OvereemLHPeikertAHofackerMDEffect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: a multi-center retrospective cohort studyCephalalgia20214229130110.1177/03331024211048765346442038988456 – reference: Diener H.-C., Förderreuther S, Kropp P. et al. (2022) Therapie der Migräneattacke und Prophylaxe der Migräne, S1-Leitlinie, 2022, DGN und DMKG, in: Deutsche Gesellschaft für Neurologie (Hrsg.), Leitlinien für Diagnostik und Therapie in der Neurologie. https://doi.org/leitlinie/therapie-der-migraneattacke-und-prophylaxeder-migrane-2022 – reference: RosenfeldMGMermodJJAmaraSGSwansonLWSawchenkoPERivierJValeWWEvansRMProduction of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processingNature19833041291351:CAS:528:DyaL3sXlslSmtrs%3D10.1038/304129a06346105 – reference: BasedauHSturmLMMigraine monoclonal antibodies against CGRP change brain activity depending on ligand or receptor target - an fMRI studyElife202211e771461:CAS:528:DC%2BB38XitlCmsLfE10.7554/eLife.77146356047559126581 – reference: FrerichsLMFriedmanDIGalcanezumab for the prevention of migrainePain Manag20211110111210.2217/pmt-2020-003033291980 – reference: StewartWFLiptonRBKolodnerKBValidity of the Migraine Disability Assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferersPain200088415210.1016/S0304-3959(00)00305-511098098 – reference: DriessenMTCohenJMThompsonSFReal-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraineJ Headache Pain202223561:CAS:528:DC%2BB38XhtlSms7zE10.1186/s10194-022-01415-x355781829109352 – reference: EdvinssonLThe trigeminovascular pathway: role of CGRP and CGRP receptors in migraineHeadache201757Suppl 2475510.1111/head.1308128485848 – reference: Zhu C, Guan J et al. (2019) Erenumab safety and efficacy in migraine: A systematic review and meta-analysis of randomized clinical trials. Medicine 98:e184883 – reference: SaccoSAminFAshinaMEuropean Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 updateJ Headache Pain2022236710.1186/s10194-022-01431-x356907239188162 – reference: ZiegelerCMayANon-responders to treatment with antibodies to the CGRP-receptor may profit from a switch of antibody classHeadache20206046947010.1111/head.1372931872439 – reference: RuizIPFerrándezJS-RFonfríaACEarly experiences in switching between monoclonal antibodies in patients with nonresponsive migraine in Spain: a case seriesEur Neurol202110.1159/000518899 – volume: 377 start-page: 2113 year: 2017 ident: 1593_CR8 publication-title: N Engl J Med doi: 10.1056/NEJMoa1709038 – volume-title: Clinical Neurology year: 2009 ident: 1593_CR1 – volume: 95 start-page: e2794 year: 2020 ident: 1593_CR20 publication-title: Neurology doi: 10.1212/WNL.0000000000010740 – ident: 1593_CR10 doi: 10.1097/MD.0000000000018483 – volume: 30 start-page: 272 year: 2017 ident: 1593_CR11 publication-title: Curr Opin Neurol doi: 10.1097/WCO.0000000000000438 – volume: 49 start-page: 1156 year: 2022 ident: 1593_CR9 publication-title: Clin Exp Pharmacol Physiol doi: 10.1111/1440-1681.13700 – ident: 1593_CR28 doi: 10.1007/s00115-022-01403-1 – ident: 1593_CR24 – volume: 88 start-page: 41 year: 2000 ident: 1593_CR15 publication-title: Pain doi: 10.1016/S0304-3959(00)00305-5 – ident: 1593_CR25 doi: 10.1136/ejhpharm-2021-002946 – volume: 33 start-page: 48 year: 1993 ident: 1593_CR5 publication-title: Ann Neurol doi: 10.1002/ana.410330109 – volume: 11 start-page: 101 year: 2021 ident: 1593_CR7 publication-title: Pain Manag doi: 10.2217/pmt-2020-0030 – volume: 23 start-page: 138 year: 2022 ident: 1593_CR14 publication-title: J Headache Pain doi: 10.1186/s10194-022-01498-6 – ident: 1593_CR29 doi: 10.1007/s42451-023-00550-2 – volume: 304 start-page: 129 year: 1983 ident: 1593_CR4 publication-title: Nature doi: 10.1038/304129a0 – volume: 60 start-page: 469 year: 2020 ident: 1593_CR22 publication-title: Headache doi: 10.1111/head.13729 – year: 2021 ident: 1593_CR23 publication-title: Eur Neurol doi: 10.1159/000518899 – volume: 57 start-page: 47 issue: Suppl 2 year: 2017 ident: 1593_CR6 publication-title: Headache doi: 10.1111/head.13081 – volume: 42 start-page: 291 year: 2021 ident: 1593_CR26 publication-title: Cephalalgia doi: 10.1177/03331024211048765 – volume: 11 start-page: e77146 year: 2022 ident: 1593_CR21 publication-title: Elife doi: 10.7554/eLife.77146 – volume: 23 start-page: 67 year: 2022 ident: 1593_CR18 publication-title: J Headache Pain doi: 10.1186/s10194-022-01431-x – volume: 38 start-page: 1 year: 2018 ident: 1593_CR17 publication-title: Cephalalgia doi: 10.1177/0333102417738202 – volume: 35 start-page: 805 year: 2021 ident: 1593_CR13 publication-title: CNS Drugs doi: 10.1007/s40263-021-00834-9 – volume: 41 start-page: 499 year: 2021 ident: 1593_CR19 publication-title: Cephalalgia doi: 10.1177/0333102420983282 – volume: 22 start-page: 111 year: 2021 ident: 1593_CR30 publication-title: J Headache Pain doi: 10.1186/s10194-021-01323-6 – ident: 1593_CR2 – volume: 363 start-page: 381 year: 2004 ident: 1593_CR3 publication-title: The Lancet doi: 10.1016/S0140-6736(04)15440-8 – volume: 41 start-page: 1222 year: 2021 ident: 1593_CR12 publication-title: Cephalalgia doi: 10.1177/03331024211018137 – volume: 31 start-page: 357 year: 2011 ident: 1593_CR16 publication-title: Cephalalgia doi: 10.1177/0333102410379890 – volume: 23 start-page: 56 year: 2022 ident: 1593_CR27 publication-title: J Headache Pain doi: 10.1186/s10194-022-01415-x |
| SSID | ssj0020385 |
| Score | 2.4331024 |
| Snippet | Background
Monoclonal antibodies targeting the CGRP pathway are effective and safe for prophylactic treatment of episodic (EM) and chronic migraine (CM). In... Monoclonal antibodies targeting the CGRP pathway are effective and safe for prophylactic treatment of episodic (EM) and chronic migraine (CM). In case of... BackgroundMonoclonal antibodies targeting the CGRP pathway are effective and safe for prophylactic treatment of episodic (EM) and chronic migraine (CM). In... Abstract Background Monoclonal antibodies targeting the CGRP pathway are effective and safe for prophylactic treatment of episodic (EM) and chronic migraine... |
| SourceID | doaj pubmedcentral proquest pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 59 |
| SubjectTerms | Antibodies, Monoclonal Calcitonin gene-related peptide Fremanezumab Headache Humans Internal Medicine Medicine Medicine & Public Health Migraine Migraine Disorders Monoclonal antibodies Neurology Non-responder Pain Medicine Patients Pharmacovigilance Prospective Studies |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gLojxDCzISN7BI4viR3krFUiEVoYpKvVl-ha7UzaLurlD5NUj8k_4yZhxnYXleOCZ2EsvfjD0Tz3xDyNNkyGvVsuglBwclWtaWnWCKRyWValVIuTBHb-XhSfPmVJz-UOoLY8IGeuBh4l74TmhrGy-EtI3j1loHFkvAfaYtfRtw9YU9b3SmsquF511jioyWmChXIQVujbFDouWs3tiGElv_70zMXyMlfzouTbvQ5Ba5mc1Huj8Me5tci_1tcv0oH5DfIV-PwfBjiQaVDqEaeTWj8452F3Fm-_h5NbOOTnuaOVUXFH_G0tn0A5aLiHQBlynCkmLuydUX26csLTrbd3QIHMc2uEUPXh-_w7ecfbKXe9TSxcqlLBFqM9UJfhU7TlJwfaQYtXh5l5xMXr0_OGS5DgPzoqmWTJSh0076WoYuAgylBBxhjVQuyiiE8mAEOBlKboWtLC-tDk3goNhl7RMB3T2y1c_7-IDQToJD7IQPXQNoBmF5aLiKgYPdAiKjClKNsBifScqxVsa5Sc6KlmaA0gCUJkFp6oI8Wz_zcaDo-Gvvl4j2uifSa6cbIHQmC535l9AVZHeUFZN1fmFqXWFophDwjSfrZtBWPIIBdOer1EerBjnRCnJ_EK31SLiqsWiULojeELqNoW629NOzxAgOViJSGcKjz0f5_D6uP8_Fw_8xFzvkRp0US7Ca75Kt5cUqPgJDbekeJ538BlUMPEk priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bb9MwFLZgSIgXxJ3AQEbiDSxSO7YTXtCYKBPSEJqY1LfIt2yVaDKaVmj8HH4p5zhOq3LZY2K7cXou-Wyf8x1CXkYgX-qKBacELFCCYVXeSKZF0ErrSvuYC3P8WR2dFp9mcpY23PoUVjn6xOiofedwj_wNLycY-CYlf3fxnWHVKDxdTSU0rpMbSF2GWq1n2wUXnnrF4iq8YlyoakyaKRWmzk2QFJdjNJGsBOM7H6bI3_8v0Pl37OQfB6jxuzS9Q24nQEkPBg24S66F9h65eZyOzO-TXycABVkkRqVD8Ebyb7RraLMMC9OGn-uFsXTe0sSy2lPcnqWL-RkWkAi0h8sYc0kxG4WaNqZt0cWBpUMkOTbBLXr48eQL_sj5D3P5lhrar21MG4EhA_cJPhQ7TmO0faAYxnj5gJxOP3w9PGKpMANzspismMx9U1rluPJNkMrkCgQLTlPboIKU2gEqsMrnwkgzMSI3pS-8AEvPuYuMdA_JXtu14TGhjYIVspXON4UprJdG-ELo4AUAGRC3zshklErtEms5Fs_4VsfVS6nqQZI1SLKOkqx5Rl5txlwMnB1X9n6Pwt70RL7teKNbntXJfGvXyNKYwkl428IKY4wF3OwR7VS5q3xG9kdVqZMT6OutymbkxaYZzBfPZEC43Tr2KXWBJGkZeTRo1mYmQnOsIlVmpNzRuZ2p7ra08_NIEQ6wEbkNYejrUT238_r_f_Hk6td4Sm7xaDESzGmf7K2W6_AMMNnKPo-G9xt5xzOj priority: 102 providerName: ProQuest – databaseName: SpringerOpen dbid: C24 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1ta9RAEF6kBfGL-G60lRX8poEkm32J39rSswgVKRb6bdm3tAe9nFzukPprCv0n_jJnNpuT0yr48bKzl72bmc0zmZlnCXkTgbySTR6cYBCgBJM3RctzyYIUUjbSx16Y40_i6LT-eMbPUlNYP1a7jynJuFNHt1YCm91KpLGtsP6HNyyHjXebY-yOKVrscUhhFua6xvaYW-dtPIIiU_9t8PLPKsnfUqXxCTR5QO4n6Ej3Bl0_JHdC94jcPU7J8cfk5gRAXx4pUOlQppF2MjpvabsIM9OF76uZsXTa0cSn2lN8EUtn03M8KiLQHj7G6kqKfSc_rk0XO7TobM_SoWgcx-ASPfhw8hm_5eKbuXpPDe1XNnaIUJNoTvCuKDiJhfWBYsXi1RNyOjn8cnCUpzMYcsfrcpnzwrfKClcJ3wYuTCFAh7A_ShtE4Fw6AABW-IIZbkrDCqN87Rk4dVG5SD73lGx18y48J7QVEAxb7nxbm9p6bpivmQyeAWYBc5EZKUe1aJcIyvGcjEsdAxUl9KBKDarUUZW6ysjb9ZyvAz3HP6X3UdtrSaTWjhfmi3OdPFW7litjasfh19aWGWMsQGSPwKYpXOMzsjPaik7-3utKlViWyTnc4_V6GDwV0y-g3fkqyihZIx9aRp4NprVeCZMVHhilMqI2jG5jqZsj3fQisoEDQkQaQ5j6brTPX-v6-3_x4v_EX5J7VXQhnldsh2wtF6uwC3BsaV9F7_sJfPEvoQ priority: 102 providerName: Springer Nature |
| Title | Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway: a subgroup analysis of the Finesse Study |
| URI | https://link.springer.com/article/10.1186/s10194-023-01593-2 https://www.ncbi.nlm.nih.gov/pubmed/37221478 https://www.proquest.com/docview/2817887552 https://www.proquest.com/docview/2818749051 https://pubmed.ncbi.nlm.nih.gov/PMC10207758 https://doaj.org/article/cf58aa4c556a4b3aaab774d818590c9d |
| Volume | 24 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3rixMxEA_nHYhfxLfVs0Twm65s89wVRHrleofQ4ygW-m1JNtm7wnWrfaD1z_EvdSb7kGoVvwR2k2yyOzPJZGfmN4S8Cop8otPI54rDAcWbKI0LGWnutdI61S7Ewowu1PlEfJzK6QFp0h3VH3C192iH-aQmy5u3375sP4DAvw8CnygMg-shwC1DzyCZ8giW5CPYmTRmNBiJ1qrA0AoWkq2wNGJc6yaIZu8zdjaqgOe_Twn905fyN4Nq2KeG98jdWsGk_Yoj7pMDXz4gt0e1Cf0h-TEG1TAKQKm0cuao1zu6KGix9HNT-u-bubF0VtIadXVF8Xctnc-uMKGEpyu4DD6YFKNTqClDGBed9y2tPMuxCm7Rwdn4Eh9y_dVs31FDVxsbwkigS4WFgoNiw2HwvvcU3Rq3j8hkePppcB7ViRqiXIreOpKxKxKrcqZc4aUysQJCwyKqrVdeSp2DlmCVi7mRpmd4bBInHAfJj1keEOoek8NyUfqnhBYKTsxW5q4QRlgnDXeCa-84KDbAU7pDeg1VsrxGMcdkGjdZOM0kKqsomQEls0DJjHXI67bP5wrD45-tT5DYbUvE3w43FsurrBbnLC9kYozIJbytsNwYY0GPdqj9pHGeug45blgla3g6Y0kPfTelhDFettUgzmijAeIuNqFNogWCpnXIk4qz2plwzTCrVNIhyQ7P7Ux1t6acXQfIcFAjEesQur5p2PPXvP7-LZ79xzyfkzssiI0EmTomh-vlxr8ARW1tu-SWiM-g1FPdJUcnpxeXY7gaMIGlGnTDD5BukFEoJ6z_E5P0P44 |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Zb9QwELZKkYAXxE2ggJHgCaJm7dhOkBAqhbKl3QpVrbRvwVfaldhs2UPV8nP4AfxGZpxkV8vRtz5ubGedzOGZzMw3hLwIhnym8thbycFB8TrOk1LEinsllcqVC7UwvQPZPU4_90V_jfxqa2EwrbLViUFRu5HFb-SbLOtg4psQ7N3Z9xi7RmF0tW2hUbPFnp-fg8s2ebv7Aej7krGdj0fb3bjpKhBbkXamsUhcmRlpmXSlF1InEnYFEq-Ml14IZeFIM9IlXAvd0TzRmUsdBzZNmA1wanDfK-QqHLwJOnuqv3TwMMoWmrmwPGZc5m2RTiaxVK-DILwMs5dEzmO2chCGfgH_MnL_ztX8I2AbzsGdW-RmY8DSrZrjbpM1X90h13pNiP4u-XkIpmccgFhpnSzS6FM6Kmk59kNd-R-zoTZ0UNEG1XVC8XMwHQ5OsGGFpxP4GXI8KVa_UF2FMjE63DK0zlzHIbhEtz8dfsGbnJ7r-Ruq6WRmQpkKLKmxVvBPceJOyO73FNMm5_fI8aWQ7D5Zr0aVf0hoKcEjN8K6MtWpcUJzl3LlHQfDCdhLRaTTUqWwDUo6Nuv4VgRvKZNFTckCKFkEShYsIq8Wa85qjJALZ79HYi9mIr53uDAanxSNuihsKTKtUyvgaVPDtdYG7HSH1lWe2NxFZKNllaJROpNiKSIReb4YBnWBMSAg7mgW5mQqRVC2iDyoOWuxE64Ydq3KIpKt8NzKVldHqsFpgCQHMxWxFGHp65Y9l_v6_7t4dPFjPCPXu0e9_WJ_92DvMbnBgvQIEK0Nsj4dz_wTsAen5mkQQkq-XrbU_wZPcG9e |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLZGJ028oHEPG2AkeIJoqR3bCRJCu5WNsaqqmLS3zI6drRJNRy-ays_hZ_DrOMdJOpXL3vbY2E6dnIvPyTnnO4S89oZ8otLQ5ZKDg-J0mEaFCBV3SiqVKutrYY678uAk_nwqTlfIr6YWBtMqG53oFbUd5fiNfIslbUx8E4JtFXVaRG-v8_Hye4gdpDDS2rTTqFjkyM2vwH2bfDjcA1q_Yayz_3X3IKw7DIS5iNvTUES2SIzMmbSFE1JHEnYI0q-Mk04IlcPxZqSNuBa6rXmkExtbDiwbsdxDq8F975BVhV5Ri6zu7Hd7_YW7hzE339qFpSHjMm1KdhKJhXtthORlmMskUh6ypWPRdw_4l8n7d-bmH-Fbfyp21sm92pyl2xX_3ScrrnxA1o7rgP1D8rMPhmjoYVlplTpSa1c6KmgxdkNduh-zoTZ0UNIa43VC8eMwHQ7OsX2FoxP46TM-KdbCUF36ojE63Da0ymPHIbhEdz_1e3iTiys9f081ncyML1qBJRXyCv4pTuz4XH9HMYly_oic3ArRHpNWOSrdU0ILCf65EbktYh0bKzS3MVfOcjCjgNlUQNoNVbK8xkzH1h3fMu87JTKrKJkBJTNPyYwF5O1izWWFGHLj7B0k9mImon37C6PxeVYrjywvRKJ1nAt42thwrbUBq92irZVGeWoDstmwSlaroEl2LTABebUYBuWBESEg7mjm5yQqRoi2gDypOGuxE64Y9rBKApIs8dzSVpdHysGFBygHoxWRFWHpu4Y9r_f1_3fx7ObHeEnWQOKzL4fdow1yl3nhESBZm6Q1Hc_cczAOp-ZFLYWUnN224P8G5rZ0-Q |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Real-world+effectiveness+of+fremanezumab+in+patients+with+migraine+switching+from+another+mAb+targeting+the+CGRP+pathway%3A+a+subgroup+analysis+of+the+Finesse+Study&rft.jtitle=Journal+of+headache+and+pain&rft.au=Straube%2C+Andreas&rft.au=Broessner%2C+Gregor&rft.au=Gaul%2C+Charly&rft.au=Hamann%2C+Xenia&rft.date=2023-05-23&rft.issn=1129-2377&rft.eissn=1129-2377&rft.volume=24&rft.issue=1&rft.spage=59&rft_id=info:doi/10.1186%2Fs10194-023-01593-2&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1129-2377&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1129-2377&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1129-2377&client=summon |